Investors' expectations of strong revenue performance and higher forecasted growth than the rest of the Medical Equipment industry are keeping the P/S ratio high. Shareholders' confidence in future revenues suggests the share price won't fall significantly soon.
Investors maintain STAAR Surgical's high P/E, anticipating its market outperformance. The robust earnings forecast revealed by company analysts likely contributes to its high P/E. Shareholders display confidence in future earnings, bolstering share price.
$STAAR Surgical(STAA.US)$ Many across the world have already gotten ICL implanted into their eyes to correct their Myopia. “Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again. FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
STAAR Surgical股票讨论区
The best investment biotech biomed stock
2023Q1营收增长16.3%,营业利润受费用大幅增长影响下滑77%,净利润下滑72%,利润增长似乎遇到了瓶颈。
目前65倍市盈率,市盈率TTM增长到了79倍,缺乏吸引力。
Load any dips below 55
专栏Top upgrades and downgrades on 4/8
• $Afya Ltd(AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio(APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $罗宾逊物流(CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang(CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver(GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc(ITT.US)$: UBS Upgr...
专栏Today's pre-market stock movers: TSLA, AAPL, POLY and more
• $Plantronics(POLY.US)$ +50% (to be acquired by HP Inc ($惠普(HPQ.US)$) for $40.00 per share)
• $Axsome Therapeutics(AXSM.US)$ +21.6% (Jazz Pharma divests Sunosi to Axsome Therapeutics)
• $STAAR Surgical(STAA.US)$ +15.4% (receives FDA approval of EVO Visian Implantable Collamer Lenses)
• $Sarcos Technology & Robotics(STRC.US)$ +7.6% (announces that the Company has reached a definitive merger agreement to acquire Pittsburgh-base...
Fantastic News!!!
Many across the world have already gotten ICL implanted into their eyes to correct their Myopia.
“Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again.
FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
专栏Top upgrades and downgrades on 3/18
• $好事达(ALL.US)$: Raymond James Upgrades to Strong Buy from Outperform - PT $165 (from $145)
• $DigitalBridge Group(DBRG.US)$: JPMorgan Upgrades to Neutral from Underweight - PT $7
• $佳明(GRMN.US)$: BofA Securities Upgrades to Buy from Neutral - PT $140 (from $165)
• $Guidewire Software(GWRE.US)$: JMP Securities Upgrades to Market Outperform from Market Perform - PT $110
• $MongoDB(MDB.US)$: UBS Upgrades to Buy from Neutral - PT $450 (from $345)...
暂无评论